As a result, the FDA has licensed four anti-CD19 CAR T-cells for aggressive B-cell lymphoma (axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel and lisocabtagene ciloleucel). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.